# Jonathan E. Rosenberg

Source: https://onco.cc/people/jonathan-rosenberg/  
OnCo record `jonathan-rosenberg` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the early enfortumab vedotin trials and the atezolizumab study that first brought immunotherapy to bladder cancer.

## Summary

Jonathan Rosenberg led IMvigor210, the first pivotal study of a PD-L1 inhibitor in urothelial cancer, and EV-201, the trial that won enfortumab vedotin accelerated approval, and was a lead investigator of EV-103 and EV-302. He has also led erdafitinib and other FGFR3-directed studies. He chairs GU oncology at MSKCC and the Alliance GU committee.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: urothelial; adc; immunotherapy
- Role: Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center
- Specialisms: Urothelial cancer; Antibody-drug conjugates; FGFR-targeted therapy; Immunotherapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Rosenberg%20JE%5BAuthor%5D%20urothelial%20enfortumab

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [Nectin-4](https://onco.cc/targets/nectin4/), [PD-L1](https://onco.cc/targets/pdl1/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Enfortumab vedotin](https://onco.cc/drugs/enfortumab-vedotin/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- trials: [EV-302 / KEYNOTE-A39](https://onco.cc/trials/ev-302/)
- key papers: [EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer](https://onco.cc/key-papers/paper-ev-302-nejm-2024/)

---
JSON: https://onco.cc/api/v1/entities/jonathan-rosenberg.json